Diese Präsentation wurde erfolgreich gemeldet.
Wir verwenden Ihre LinkedIn Profilangaben und Informationen zu Ihren Aktivitäten, um Anzeigen zu personalisieren und Ihnen relevantere Inhalte anzuzeigen. Sie können Ihre Anzeigeneinstellungen jederzeit ändern.
Presenter:
#NOhep
HCV Treatment Access across
Europe
Raquel Peck
CEO
World Hepatitis Alliance Raqpeck
#NOhep
Current Environment
69th WHA: 194 govts commit to
eliminating viral hepatitis by 2030
#NOhep
GHSS on viral hepatitis: relevance
• 100% of blood donations
screened in a quality-assured
manner
• 90% of injectio...
#NOhep
HCV and the EU
The 28 EU countries account for nearly 70% of the total European population
Countries in the Europea...
#NOhep
HCV in the EU - continued
-
50,000
100,000
150,000
200,000
250,000
300,000
350,000
400,000
450,000
500,000
TotalVir...
#NOhep
10 countries accounted for 85% of viremic HCV infections.
0
200,000
400,000
600,000
800,000
1,000,000
1,200,000
1,4...
#NOhep
6 countries accounted for 80% of treated patients.
HCV in the EU - continued
7.9%
9.3%
2.1%
10.2%
4.8%
3.0%
0.7%
1....
#NOhep
EU Case Studies
France
Germany
Portugal
France will provide access to hepatitis C treatment with direct-acting anti...
#NOhep
EU Case Studies - continued
Country HCV Patient Starts
in 2013
HCV Patient Starts in
2014
HCV Patient Starts
in 201...
#NOhep
Non-EU Case Study
• Civil Society pressure; Govt
played hard-ball w/ industry
• Deal with industry AUS 1billion ove...
#NOhep
HCV Elimination in EU
• Active Screening
• Strong prevention efforts
• Switch to direct acting antivirals with high...
#NOhep
Thank you!
www.worldhepatitisalliance.org
Hep_Alliance
https://www.facebook.com/worldhepalliance
www.nohep.org
Nächste SlideShare
Wird geladen in …5
×

HCV Treatment Access across Europe - Raquel Peck

176 Aufrufe

Veröffentlicht am

Raquel Peck's presentation Uniting Voices for HCV Elimination Meeting, 4/7/16

Veröffentlicht in: Gesundheit & Medizin
  • Als Erste(r) kommentieren

  • Gehören Sie zu den Ersten, denen das gefällt!

HCV Treatment Access across Europe - Raquel Peck

  1. 1. Presenter: #NOhep HCV Treatment Access across Europe Raquel Peck CEO World Hepatitis Alliance Raqpeck
  2. 2. #NOhep Current Environment 69th WHA: 194 govts commit to eliminating viral hepatitis by 2030
  3. 3. #NOhep GHSS on viral hepatitis: relevance • 100% of blood donations screened in a quality-assured manner • 90% of injections given with safety-engineered devices • The distribution of at least 300 sterile needles and syringes to each person who injects drugs every year • 90% of people with hepatitis B and hepatitis C diagnosed • 80% of people with hepatitis B and hepatitis C treated
  4. 4. #NOhep HCV and the EU The 28 EU countries account for nearly 70% of the total European population Countries in the European Union (population ~510 million) Austria Estonia Italy Portugal Belgium Finland Latvia Romania Bulgaria* France Lithuania Slovakia Croatia Germany Luxembourg Slovenia Cyprus* Greece Malta Spain Czech Republic Hungary Netherlands Sweden Denmark Ireland Poland United Kingdom HCV disease burden models have been validated for 26 countries in the EU (98% of the EU population represented). The model for Bulgaria has not been validated by local experts. No assessment of Cyprus was conducted for this analysis.
  5. 5. #NOhep HCV in the EU - continued - 50,000 100,000 150,000 200,000 250,000 300,000 350,000 400,000 450,000 500,000 TotalViremicInfected(2016) EU: 3.6M viremic infections, 1.2M already diagnosed. In 2015, 133,000 patients were treated and 97,000 were cured. Median Age: 54 years. Median Age: 54 Source: Polaris Observatory (http://www.polarisobservatory.com/)
  6. 6. #NOhep 10 countries accounted for 85% of viremic HCV infections. 0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 Viremic HCV Infections (2015) 85% of Total HCV in the EU - continued Source: Polaris Observatory (http://www.polarisobservatory.com/)
  7. 7. #NOhep 6 countries accounted for 80% of treated patients. HCV in the EU - continued 7.9% 9.3% 2.1% 10.2% 4.8% 3.0% 0.7% 1.8% 5.8% 10.2% 6.9% 1.3% 2.0% 2.3% 2.1% 2.0% 2.7% 3.3% 3.3% 0.6% 1.3% 1.0% 1.3% 0.6% 2.3% 3.3% 1.0% - 5,000 10,000 15,000 20,000 25,000 30,000 35,000 40,000 45,000 Number Treated & Treatment Rate 80% of Total Source: Polaris Observatory (http://www.polarisobservatory.com/)
  8. 8. #NOhep EU Case Studies France Germany Portugal France will provide access to hepatitis C treatment with direct-acting antivirals to everyone diagnosed with HCV from September 2016, and will begin to provide treatment to everyone with F2 immediately (May announcement). Up to 230,000 people in France with hepatitis C could be treated under the new rules but the prices paid by the French health system for direct-acting antivirals must be renegotiated (indications for prescribing of drugs has expanded, increasing the size of the market; competitor products are becoming available). Following great advocacy work by national NGOs, aided by an influential member of parliament, the MoH committed to eliminating HCV. Prices of 13,000 euros are believed to have been achieved in confidential deals, in which government pay nothing for people who are not cured and the cost of treatment is the same regardless of duration. Oral treatment approved for al patients. Strong civil society advocacy. Eco-hep model: 2 scenarios A) Maintain current treatment (25,000p/yr) and screening rates (3.5%). Cost = EUR 13.2b by 2040 B) Maintain tx rates (25,000 p/yr), target screening, prevention efforts. Costs = EUR 14.2b by 2040
  9. 9. #NOhep EU Case Studies - continued Country HCV Patient Starts in 2013 HCV Patient Starts in 2014 HCV Patient Starts in 2015 Germany 12,000 Not available 25,000 France 4,400 11,600 14,000 UK 5,000 5,000 5,700 Portugal 900 910 7,632
  10. 10. #NOhep Non-EU Case Study • Civil Society pressure; Govt played hard-ball w/ industry • Deal with industry AUS 1billion over 5years • Scaling up treatment; GPs prescribing meds • Payment: as of March 1st, usual co- payment price for the dispensing fee of each prescription; $38.30 ($6.20 for concessional patients) • 2015: 2,500 ppl treated • 2016: March-April: ~15,000 ppl treated AUSTRALIA
  11. 11. #NOhep HCV Elimination in EU • Active Screening • Strong prevention efforts • Switch to direct acting antivirals with higher SVR • Expand treatment to all patients (>=F0) Most new infections occur among younger individuals who are F0 or F1 • To reduce liver related deaths, eligibility has to increase to older patients – median age in EU is 54, and in 11 years half of the HCV infected population will be ineligible for treatment (if those above 65 are ineligible for treatment) STRONG PATIENT VOICE
  12. 12. #NOhep Thank you! www.worldhepatitisalliance.org Hep_Alliance https://www.facebook.com/worldhepalliance www.nohep.org

×